SEC Form 4 · accession 0001470831-26-000883
Bicara Therapeutics Inc. · BCAX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ryan Cohlhepp
Officer — President, COO & Interim CEO · Director
Period of report
Sep 8, 2026
Accepted (ET)
Sep 10, 2026 · 4:23 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0002023658
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 8, 2026 | M | 17,500 | $3.7898 | A | 199,141 | D | |
| Common StockF2 | Sep 8, 2026 | S | 14,058 | $22.7666 | D | 185,083 | D | |
| Common StockF3 | Sep 8, 2026 | S | 3,442 | $23.4349 | D | 181,641 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $3.7898 | Sep 8, 2026 | M | 17,500 | D | — | Apr 5, 2033 | Common Stock | 17,500 | 34,252 | D |
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.26 to $23.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.26 to $23.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F4The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.